Newsroom

September 28, 2021- Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

September 15, 2021- Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company.

September 14, 2021- Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs.

September 13, 2021- Sera will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21, 2021 at 8:15 a.m. Eastern Time.

August 30, 2021- Sera announced financial results for the second quarter ended June 30, 2021.

August 17, 2021- Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

July 14, 2021 – Sera today announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share.

May 19, 2021-The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

May 18, 2021-Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings

April 28, 2021-Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test.